Media

Our latest news, announcements and multimedia resources

Latest news

October 5, 2021

Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer

October 1, 2021

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

September 30, 2021

Merck to Acquire Acceleron Pharma Inc.

September 29, 2021

Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director

September 28, 2021

Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28

September 27, 2021

Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

September 23, 2021

Merck Announces Settlement and License Agreement Resolving Pneumococcal Conjugate Vaccine Patent Litigation

September 21, 2021

Building Sustainable Value for our Business and Society

Merck Statement on Clinical Data for Molnupiravir Generated by Hetero in India

Merck Provides Update on FDA’s Oncologic Drugs Advisory Committee (ODAC) Meetings on April 28-29, 2021

FDA’s Oncologic Drugs Advisory Committee to Discuss Three Indications for KEYTRUDA® (pembrolizumab) During Meetings Focused on Accelerated Approvals

February 9, 2021

Merck Announces Outcome of Oncologic Drugs Advisory Committee (ODAC) for KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Media resources

News releases

Read our latest news releases.

Company statements

Read our latest company statements.

Media library

Access videos, logos, photos and infographics.

Media contact details

General
General media inquiries

+1 908-740-5633

[email protected]

Patrick Ryan
Corporate media relations

+1 973-275-7075

[email protected]

John Cummins
Policy media relations

+1 202-508-4567

[email protected]

Get to know us through our stories

Everything we do, in and out of the laboratory, is based on our deep appreciation for life. Get a glimpse of what it's like on the inside through our stories.

Scientist reviewing test tubes

We are driven by a shared purpose to invent for life

Our mission is to discover, develop and provide innovative products and services that save and improve lives around the world.

Learn more about our company

Person reviewing product pipeline on their smartphone

Investor relations

Find our latest financials, events & presentations, news, stock information and investor contacts.

Visit investor relations

Two employees in the lobby on their laptops

Company fact sheet

Access company information including stock ticker, official company names, description, and more.

See company fact sheet

Unsubscribe from email alerts